AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7241441 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaesthetic technique used during bronchoscopy.
Number of subjects: 75
Study 31940502 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) + O2 for 24 hours
Number of subjects: 38
Study 31940502 — intervention group
Group type: COMPARATOR
Intervention: O2 only for 24 hours (Control)
Number of subjects: 38
Study 31940502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinaciguat (sGC activator)
Number of subjects: 38
Study 31940502 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (sGC stimulator)
Number of subjects: 38
Study 31940502 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 38
Study 31017569 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B complex added to prime solution for CPB (25 mg vitamin B1, 2.734 mg vitamin B2, 5 mg vitamin B6, 15 mcg vitamin B12, 50 mg niacinamide, 17.2 mg D-panthenol)
Number of subjects: 69
Study 31017569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin B complex)
Number of subjects: 69
Study 28114926 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-level, multi-component (MLMC) intervention targeting obesity prevention and reduction
Number of subjects: 0
Study 25884881 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nutritional counseling by a trained dietitian
Number of subjects: 110
Study 25884881 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 110
Study 24270456 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 24
Study 24270456 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Strength and Endurance Training ratio 3:1 (CT3)
Number of subjects: 24
Study 24270456 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Strength and Endurance Training ratio 1:1 (CT1)
Number of subjects: 24
Study 24270456 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study 21795025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) exercises including visual, auditory, and cognitive control training
Number of subjects: 14
Study 21795025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation (CR) exercises
Number of subjects: 14
Study 19516185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine-perindopril therapy
Number of subjects: 1905
Study 19516185 — intervention group
Group type: COMPARATOR
Intervention: Atenolol-thiazide therapy
Number of subjects: 1905
Study 19516185 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic systolic BP
Number of subjects: 1905
Study 19516185 — intervention group
Group type: EXPERIMENTAL
Intervention: Daytime systolic BP
Number of subjects: 1905
Study 19516185 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time systolic BP
Number of subjects: 1905
Study 18086990 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure hemorrhoidectomy
Number of subjects: 525
Study 18086990 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemorrhoidectomy
Number of subjects: 525
Study 15176293 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuberculostatic drugs + vitamins C (1.0 g) and E (600 mg) after 1-month therapy
Number of subjects: 40
Study 15176293 — intervention group
Group type: COMPARATOR
Intervention: Tuberculostatic drugs
Number of subjects: 40
Study 15176293 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 clinically healthy subjects)
Number of subjects: 40
Study 11482141 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical compaction
Number of subjects: 70
Study 11482141 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral compaction
Number of subjects: 70
Study 11482141 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 70
Study 11482141 — intervention group
Group type: COMPARATOR
Intervention: Positive control
Number of subjects: 70
Study 11482141 — intervention group
Group type: COMPARATOR
Intervention: Negative control
Number of subjects: 70
Study 11482141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye leakage
Number of subjects: 70
Study 9724682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurement in patients with myelomeningocele
Number of subjects: 35
Study 9724682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurement in patients with multiple fractures
Number of subjects: 35
Study 9724682 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary pyridinoline levels measurement
Number of subjects: 35
Study 9724682 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary calcium excretion measurement
Number of subjects: 35
Study 9724682 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density measurement by age and sex
Number of subjects: 35
Study 9186334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate
Number of subjects: 95
Study 9186334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrosurgical vaporization
Number of subjects: 95
Study 9186334 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual laser ablation
Number of subjects: 95
Study 9186334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal high intensity focused ultrasound
Number of subjects: 95
Study 9186334 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral needle ablation
Number of subjects: 95
Study 9186334 — intervention group
Group type: COMPARATOR
Intervention: All procedures
Number of subjects: 95
Study 1785235 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlimited access to oral water until 2 hours before anaesthesia
Number of subjects: 0
Study 1785235 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 7131548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 100
Study 7131548 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 100
Study 7131548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg) for high-nicotine-dependent smokers
Number of subjects: 100
Study 7131548 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum for high-nicotine-dependent smokers
Number of subjects: 100
Study 7131548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg) for low-nicotine-dependent smokers
Number of subjects: 100
Study 7131548 — intervention group
Group type: COMPARATOR
Intervention: Placebo chewing gum for low-nicotine-dependent smokers
Number of subjects: 100
Study 31355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge preservation using freeze-dried bone allograft (FDBA)
Number of subjects: 79
Study 31355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresorbable dense polytetrafluoroethylene (dPTFE) membrane
Number of subjects: 79
Study 31355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable collagen sponge
Number of subjects: 79
Study 31355447 — intervention group
Group type: COMPARATOR
Intervention: Extraction alone (control)
Number of subjects: 79
Study 31355447 — intervention group
Group type: EXPERIMENTAL
Intervention: Ridge preservation using FDBA
Number of subjects: 79
Study 29421829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) intervention, 8 sessions
Number of subjects: 113
Study 29421829 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 113
Study 27379953 — intervention group
Group type: COMPARATOR
Intervention: 0% maltodextrin
Number of subjects: 15
Study 27379953 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% maltodextrin
Number of subjects: 15
Study 27379953 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% maltodextrin
Number of subjects: 15
Study 27379953 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% maltodextrin
Number of subjects: 15
Study 25647781 — intervention group
Group type: EXPERIMENTAL
Intervention: Axitinib/gemcitabine
Number of subjects: 632
Study 25647781 — intervention group
Group type: COMPARATOR
Intervention: Placebo/gemcitabine
Number of subjects: 632
Study 25035126 — intervention group
Group type: COMPARATOR
Intervention: Self-moulded MAD (SleepPro 1; SP1)
Number of subjects: 90
Study 25035126 — intervention group
Group type: COMPARATOR
Intervention: Semi-bespoke MAD (SleepPro 2; SP2)
Number of subjects: 90
Study 25035126 — intervention group
Group type: COMPARATOR
Intervention: Fully-bespoke MAD (bMAD)
Number of subjects: 90
Study 25035126 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 90
Study 22865999 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-motor exercise program (twice weekly for 12 weeks) including strength and balance training and dance video gaming
Number of subjects: 0
Study 22865999 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention)
Number of subjects: 0
Study 20021688 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape recording and verbal feedback
Number of subjects: 52
Study 20021688 — intervention group
Group type: COMPARATOR
Intervention: Verbal feedback alone
Number of subjects: 52
Study 17479539 — intervention group
Group type: EXPERIMENTAL
Intervention: New retard tablet formulation of verapamil (240 mg oral dose)
Number of subjects: 12
Study 17479539 — intervention group
Group type: COMPARATOR
Intervention: Standard retard tablet formulation of verapamil (240 mg oral dose)
Number of subjects: 12
Study 17479539 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (i.v.) dose of verapamil (5 mg)
Number of subjects: 12
Study 15045502 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary exercise (leg extension‐flexion movement for 20 s with weights corresponding to 5% of body mass)
Number of subjects: 22
Study 15045502 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive movement (experimenter pulling ropes connected to subjects' ankles for 20 s)
Number of subjects: 22
Study 15045502 — intervention group
Group type: COMPARATOR
Intervention: Passive movement
Number of subjects: 22
Study 15045502 — intervention group
Group type: COMPARATOR
Intervention: Voluntary exercise
Number of subjects: 22
Study 12126596 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 980
Study 12126596 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 980
Study 9113177 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg/kg morphine in 60 ml saline administered intravenously into the exsanguinated operative limb
Number of subjects: 50
Study 9113177 — intervention group
Group type: COMPARATOR
Intervention: 60 ml saline administered intravenously into the operative leg and 0.125 mg/kg morphine intramuscularly into the opposite leg
Number of subjects: 50
Study 1586526 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult test kit posted without health check invitation
Number of subjects: 1588
Study 1586526 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult test kit posted with health check invitation
Number of subjects: 1588
Study 1586526 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check invitation posted with Haemoccult test kit offered at health check
Number of subjects: 1588
Study 1586526 — intervention group
Group type: COMPARATOR
Intervention: Health check invitation posted without Haemoccult test kit
Number of subjects: 1588
Study 1586526 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult test kit enclosed with health check invitation
Number of subjects: 1588
Study 1586526 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult test kit offered at health check
Number of subjects: 1588
Study 2580181 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus a thiazide diuretic (37.5-75 mg/day)
Number of subjects: 270
Study 2580181 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus a diuretic (60-120 mg/day)
Number of subjects: 270
Study 2580181 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril plus a thiazide diuretic
Number of subjects: 270
Study 2580181 — intervention group
Group type: COMPARATOR
Intervention: Propranolol plus a diuretic
Number of subjects: 270
Study 29373148 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 74
Study 29305130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet intervention
Number of subjects: 7170
Study 29305130 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 7170
Study 29305130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable intake (part of Mediterranean diet)
Number of subjects: 7170
Study 26599222 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation (2.8 g/day)
Number of subjects: 35
Study 26599222 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24604348 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact lenses
Number of subjects: 114
Study 24604348 — intervention group
Group type: COMPARATOR
Intervention: Intraocular lenses (IOL)
Number of subjects: 114
Study 21798763 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐CASI screening and referral
Number of subjects: 126
Study 21798763 — intervention group
Group type: COMPARATOR
Intervention: HCP screening and referral
Number of subjects: 126
Study 21798763 — intervention group
Group type: COMPARATOR
Intervention: A‐CASI referral with HCP endorsement
Number of subjects: 126
Study 21798763 — intervention group
Group type: COMPARATOR
Intervention: A‐CASI alone
Number of subjects: 126
Study 20410835 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment EFS
Number of subjects: 840
Study 20410835 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment stress-corrected EFS
Number of subjects: 840
Study 20410835 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment MWS
Number of subjects: 840
Study 20410835 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment stress-corrected MWS
Number of subjects: 840
Study 18656314 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily smokers
Number of subjects: 72
Study 18656314 — intervention group
Group type: COMPARATOR
Intervention: Nonsmokers
Number of subjects: 72
Study 18656314 — intervention group
Group type: EXPERIMENTAL
Intervention: Chippers
Number of subjects: 72
Study 15943950 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone treatment in a Primary Care Clinic (PCC) for 26 weeks
Number of subjects: 96
Study 15943950 — intervention group
Group type: COMPARATOR
Intervention: Methadone maintenance treatment in an Opioid Treatment Program (OTP)
Number of subjects: 96
Study 11814492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 microg plus norgestrel 300 microg starting on menstrual cycle day 1
Number of subjects: 130
Study 11814492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 microg plus norgestrel 300 microg starting on menstrual cycle day 4
Number of subjects: 130
Study 11814492 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 30 microg plus norgestrel 300 microg starting on menstrual cycle day 7
Number of subjects: 130
Study 11814492 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 130
Study 10530860 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructed ACL using autogenous semitendinosus and gracilis tendons
Number of subjects: 32
Study 10530860 — intervention group
Group type: COMPARATOR
Intervention: Injured ACL
Number of subjects: 32
Study 10530860 — intervention group
Group type: COMPARATOR
Intervention: Normal ACL
Number of subjects: 32
Study 7489471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 29
Study 7489471 — intervention group
Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 29
Study 1987818 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 263
Study 1987818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 6366133 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (Cyclophosphamide, Methotrexate, 5-Fluorouracil + Vincristine + Prednisone)
Number of subjects: 401
Study 6366133 — intervention group
Group type: COMPARATOR
Intervention: CMF (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 401
Study 6366133 — intervention group
Group type: EXPERIMENTAL
Intervention: CMF-MER (Cyclophosphamide, Methotrexate, 5-Fluorouracil + Methanol Extraction Residue of BCG)
Number of subjects: 401
Study 6366133 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 401
Study 31479105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily
Number of subjects: 120
Study 31479105 — intervention group
Group type: COMPARATOR
Intervention: Dose-adjusted warfarin
Number of subjects: 120
Study 31479105 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 120
Study 31479105 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 120
Study 29685792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU daily for 12 months
Number of subjects: 305
Study 29685792 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU daily for 12 months
Number of subjects: 305
Study 29685792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 27737356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdentures supported by two implants with bar‐clip system and a maxillary conventional denture (n = 25)
Number of subjects: 50
Study 27737356 — intervention group
Group type: COMPARATOR
Intervention: New maxillary and mandibular conventional complete dentures (n = 25)
Number of subjects: 50
Study 27737356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular overdentures supported by two implants with bar‐clip system
Number of subjects: 50
Study 27737356 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 50
Study 24768939 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (physical exercise, nutrition, cognitive training)
Number of subjects: 0
Study 24768939 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 22664690 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to music
Number of subjects: 69
Study 22664690 — intervention group
Group type: COMPARATOR
Intervention: No music (Control)
Number of subjects: 69
Study 19562361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dictation of the letter to the GP in front of the patient
Number of subjects: 100
Study 19562361 — intervention group
Group type: COMPARATOR
Intervention: Non-dictation of the letter to the GP
Number of subjects: 100
Study 19562361 — intervention group
Group type: COMPARATOR
Intervention: Non-dictation group
Number of subjects: 100
Study 19562361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dictation group
Number of subjects: 100
Study 17685675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushing the motor vehicle (MV)
Number of subjects: 6
Study 17685675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulling the motor vehicle (MV)
Number of subjects: 6
Study 17685675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pushing and pulling the MV
Number of subjects: 6
Study 15772563 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/d
Number of subjects: 619
Study 15772563 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 150 mg/d
Number of subjects: 619
Study 15772563 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen 0.625 mg/d
Number of subjects: 619
Study 15772563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 619
Study 12130970 — intervention group
Group type: EXPERIMENTAL
Intervention: H2-blockers
Number of subjects: 0
Study 9695541 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous occurrence of Pulfrich's stereophenomenon in retrobulbar neuritis patients
Number of subjects: 49
Study 9695541 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous occurrence of Pulfrich's stereophenomenon in demyelinating patients
Number of subjects: 49
Study 9695541 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulfrich's pendulum test in demyelinating patients
Number of subjects: 49
Study 8082084 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger than 2 years of age at diagnosis
Number of subjects: 0
Study 8082084 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumors weighing less than 550 g
Number of subjects: 0
Study 8082084 — intervention group
Group type: COMPARATOR
Intervention: Tumors weighing more than 550 g
Number of subjects: 0
Study 2692062 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group patients
Number of subjects: 85
Study 2692062 — intervention group
Group type: COMPARATOR
Intervention: Control group patients
Number of subjects: 85
Study 4916196 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 220
Study 4916196 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 220
Study 31843839 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐component in‐hospital intervention
Number of subjects: 20
Study 31843839 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 20
Study 28133947 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming Group (GG)
Number of subjects: 44
Study 28133947 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 44
Study 24849000 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CG)
Number of subjects: 60
Study 24849000 — intervention group
Group type: COMPARATOR
Intervention: Povidone iodine (PI)
Number of subjects: 60
Study 22595983 — intervention group
Group type: EXPERIMENTAL
Intervention: Room air
Number of subjects: 16
Study 22595983 — intervention group
Group type: COMPARATOR
Intervention: 50% supplemental O2
Number of subjects: 16
Study 20537177 — intervention group
Group type: EXPERIMENTAL
Intervention: Network meta-analysis combining count and hazard ratio statistics
Number of subjects: 0
Study 18566295 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 11
Study 18566295 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate (200 mg/d)
Number of subjects: 11
Study 18566295 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Fenofibrate
Number of subjects: 11
Study 16038387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic bubble trap (DBT)
Number of subjects: 12